title: Exocannabinoids effect on in vitro bovine oocyte maturation via activation of AKT and ERK1/2.
abstract: Endocannabinoids are known to mediate practically all reproductive events in mammals; however, little is known about their role in oocyte maturation. Through RT-PCR and immunocytochemistry, this study confirms the presence of CB1 and CB2 cannabinoid receptors in bovine oocytes and shows how exposure to the exogenous cannabinoids HU-210 and THC during their in vitro maturation (IVM) activates the phosphorylation of AKT and ERK1/2 proteins associated with the resumption of meiosis. Although supplementation with HU-210 or THC during IVM did not increase blastocyst yields, the expression of interferon tau (IFNτ) and gap junction alpha-1 protein (GJA1) was enhanced at the blastocyst stage. Our data suggest that cannabinoid agonists may be useful IVM supplements as their presence during oocyte maturation upregulates the expression in blastocysts of key genes for embryo quality.
authors: Departamento de Reproducción AnimalINIA, Madrid, Spain angeladir7@gmail.com.|G.I. BiogénesisUniversidad de Antioquia, Medellín, Colombia.
authors: A P
authors: AP
authors: López-Cardona
authors: Departamento de Reproducción AnimalINIA, Madrid, Spain.
authors: M J
authors: MJ
authors: Sánchez-Calabuig
authors: Departamento de Reproducción AnimalINIA, Madrid, Spain.
authors: P
authors: P
authors: Beltran-Breña
authors: Department of PhysiologyFaculty of Medicine and Dentistry UPV/EHU, Leioa, Bizkaia, Spain.
authors: N
authors: N
authors: Agirregoitia
authors: Departamento de Reproducción AnimalINIA, Madrid, Spain.
authors: D
authors: D
authors: Rizos
authors: Department of PhysiologyFaculty of Medicine and Dentistry UPV/EHU, Leioa, Bizkaia, Spain.
authors: E
authors: E
authors: Agirregoitia
authors: Departamento de Reproducción AnimalINIA, Madrid, Spain.
authors: A
authors: A
authors: Gutierrez-Adán
mesh_terms: D000818:Animals; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology; D002417:Cattle; D002478:Cells, Cultured; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D047108:Embryonic Development / Q000187:drug effects; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D059471:In Vitro Oocyte Maturation Techniques; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D009865:Oocytes / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D009866:Oogenesis / Q000187:drug effects / Q000502:physiology; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000378:metabolism
chemical_list: D063386:Cannabinoid Receptor Agonists; D018691:Excitatory Amino Acid Antagonists; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D013759:Dronabinol; D051057:Proto-Oncogene Proteins c-akt; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; C062018:HU 211